Non-diabetic use of liraglutide

Verma, Abhyudaya

doi:10.4103/2230-8210.100698

Cited by 1 publication

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A weight loss of 8 kg (±2.4 kg) from a baseline weight of 110 kg (±12.5 kg), and waist circumference reduction of 3.1 cm (±1.2 cm) from a baseline waist circumferences of 114 cm (±8.1 cm) was observed among 25 obese non-diabetic subjects after 12 weeks of liraglutide therapy, with a dose of 1.2 mg (Verma, 2012). [17] Significant reduction of mean body weight (from 96.33 ± 14.45 at baseline to 90 ± 13.47 at 3 months and to 86.25 ± 13.19 at 9 months, P < 0.001), BMI (from 34.99 ± 5.66 at baseline to 32.66 ± 5.17 at 3 months to 31.29 ± 4.97 at 9 months, P < 0.001), and waist circumference (from 93.33 ± 5.43 at baseline to 90.33 ± 5.09 at 3 months to 88.5 ± 4.59 at 9 months, P < 0.001) were reported after 3 and 9 months of liraglutide treatment, with a dose of 1.8 mg (Roy et al 2016). [16] Even a low dose (0.6 mg) of liraglutide showed a reduction of 6.03 kg over 24 weeks.…”

Section: Discussionmentioning

confidence: 99%

“…Ten observational studies have recently been published with liraglutide in a real-world setting (Jothydev et al , Kaur et al , Sanyal et al , Roy Chaudhri et al , Wagnoo et al , Verma et al , and Majumder et al ), from various parts of India. [10111213141516171819] We are presenting a review of the real-world experience with liraglutide in India.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liraglutide – Indian experience

Majumder

Soumyabrata

Sanyal

et al. 2018

Indian J Endocr Metab

View full text Add to dashboard Cite

Liraglutide is an effective drug for the treatment of type 2 diabetes mellitus (T2DM). The aim of this review is to collate evidence on the real-world clinical effectiveness of liraglutide from the published Indian studies. A review of publications was conducted to identify observational studies that assessed the effectiveness of liraglutide among Indian T2DM. Total ten publications were retrieved and these observational studies are compared with the results of the liraglutide randomized controlled trial (RCT) program (Liraglutide Effect and Action in Diabetes [LEAD]). Liraglutide therapy demonstrated HbA1c reduction in the Indian population up to 2.26% and 2.54%, over 24 and 52 weeks, respectively. Among the LEAD trials, the HbA1c reduction at 24 weeks was maximum in LEAD-4 with 1.5% reduction at both doses used (1.2 and 1.8 mg) and up to 1.14% in LEAD-3 with a dose of 1.8 mg. The weight loss among Indian subjects was generally around 5 kg or more with maximum weight loss of 8.6 kg over 24 weeks. The maximal weight loss in LEAD studies was less than 3 kg with an exception of 3.24 kg in LEAD-6. In over 52 weeks of liraglutide therapy among Indian subjects, mean weight loss was 7.4 kg, which was 3.5 times more than of LEAD program. Two Indian observational studies also demonstrated significant weight loss among nondiabetic obese subjects at a much lower than that of 3 mg anti-obesity dose. Gastrointestinal (GI) events are the commonly reported adverse events with Indian studies as well as LEAD program. Liraglutide therapy produces better glycemic control and more weight loss among Indian T2DM subjects compared with RCTs conducted in western population with almost similar adverse consequences.

show abstract

Section: Discussionmentioning

confidence: 99%